TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06736860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA) injection
Description: All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. The 1+1 control group continued to infuse 1g TXA within 8 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) injection
Description: All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. the 1+x study group was subjected to thromboelastography (TEG) without TXA for the time being, and the coagulation and fibrinolytic status of the patients was judged according to the results of TEG (LY30, EPL value), and the patients diagnosed with hyperfibrinolysis continued to be infused with 1g TXA, and the patients diagnosed with normal or reduced fibrinolysis were not infused with TXA. TEG was rechecked after 4 h, and the decision of whether to use TXA was based on the TEG results.
Study: NCT06740565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic endovascular aortic repair
Description: stent-graft implanted to seal the proximal entry tear of type B aortic dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic endovascular aortic repair
Description: stent-graft implanted to seal the proximal entry tear of type B aortic dissection
Study: NCT06737926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor Training Exercise
Description: Participants will perform sensorimotor training exercises designed to improve balance, reduce pain intensity, and enhance functional exercise capacity. The program will include progressive exercises focusing on proprioception, neuromuscular coordination, and functional mobility. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.
Study: NCT04718753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful breathing intervention
Description: Mindful breathing intervention audio, which is used in mindfulness-based interventions, will be sent to the participants once per day.
Study: NCT05307107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHINE
Description: Intervention group will use a 8-workweeks the digital Smart Break SHINE program with workplace support (encouragement and time-support) including daily 3 minutes break exercises twice a day; 1) physical exercise - break and 2) body/mind breathing exercise - break earning stars for exercise completed. The program includes weekly self-reflective task of individual well-being during working hours with weekly changing theme (avoiding sitting time, nature benefits, relaxation exercises, increasing physical activity in workplace etc.) earning diamonds for every weekly task completed. Participants self-monitors their weekly individual resources levels asked in every Thursday (1-5, 1= very poor. 5= very good). Program includes e-mail remainders set by participant themselves for suitable time frame These individual well-being actions takes approximately 15 minutes/workday. Control group will receive this program after this study (waitlist protocol).
Study: NCT06520475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genicular nerve block using bupivacaine and magnesium
Description: The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of 10% magnesium sulfate

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: genicular nerve block using bupivacaine and normal saline
Description: The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of normal saline
Study: NCT06737926

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise Therapy
Description: Participants will undergo conventional exercise therapy, including stretching, strengthening, and aerobic exercises, based on standard physiotherapy protocols. The therapy aims to maintain joint mobility, reduce stiffness, and improve general physical fitness. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.
Study: NCT06739655

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Description: In this study the patients assigned to the experimental treatment arm will receive preoperative radiotherapy instead of postoperative radiotherapy.~This preoperative radiotherapy will follow the standard of care (SoC) principles as they are defined for postoperative radiotherapy in breast cancer, as defined by international guidelines.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative radiotherapy
Description: Standard of care (SoC) postoperative radiotherapy, as defined by international guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate breast reconstruction
Description: In the experimental arm of the PRADAIIBE, the participants will undergo immediate breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery. Using one of the following primary techniques: 1) Autologous tissue reconstruction (1 phase); 2) Tissue expander and autologous tissue reconstruction (2 phases); 3) Breast implant based reconstruction (1 phase); 4) Tissue expander and breast implant based reconstruction (2 phases); 5) Combined autologous tissue and breast implant reconstruction (1 phase); 6) Tissue expander and combined autologous tissue and breast implant reconstruction (2 phases). Adjuvant techniques are allowed to be added.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate or delayed breast reconstruction
Description: In the standard arm of the PRADAIIBE, the participants will undergo immediate or delayed breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery (immediate), or at a later time (delayed). Using one of the following primary techniques: 1) Autologous tissue reconstruction (1 phase); 2) Tissue expander and autologous tissue reconstruction (2 phases); 3) Breast implant based reconstruction (1 phase); 4) Tissue expander and breast implant based reconstruction (2 phases); 5) Combined autologous tissue and breast implant reconstruction (1 phase); 6) Tissue expander and combined autologous tissue and breast implant reconstruction (2 phases). Adjuvant techniques are allowed to be added.
Study: NCT06738524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fighting with Digital Addiction
Description: The purpose of this training is to raise awareness among young people about the signs, causes and consequences of addictive use of technology and how to avoid excessive use of technology and technology addiction.
Study: NCT06736613

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cerebral Spinal Fluid ctDNA
Description: MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019
Study: NCT06740721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: False Lumen Embolization System, IMPEDE-FX RapidFill
Description: Embolization of the false lumen of an aortic dissection
Study: NCT06741202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men's MST Group
Description: see above

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present-Centered Group Therapy
Description: see above
Study: NCT05893134

Intervention type: OTHER
Intervention: Risk Assessment
Description: A probabilistic risk model will be generated based on the variables of different natures used and maps will be built to identify the areas of greatest risk for dengue transmission in the study area
Study: NCT05133986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onion Feeding
Description: The intervention includes feeding individuals a 120g portion of onions (experimental condition).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onion Feeding
Description: The intervention includes feeding individuals a 120g portion of onions (experimental condition).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Couscous Feeding
Description: The intervention includes feeding individuals a 120g portion of couscous (control condition).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Couscous Feeding
Description: The intervention includes feeding individuals a 120g portion of couscous (control condition).

Intervention type: OTHER
Group type: OTHER
Intervention: Onion Supplementation Period
Description: Three 4-day supplementation periods separated by two 3-day washout periods. Supplementation periods will provide participants with a daily portion of onions to be consumed with their evening meals. The daily quantity of onion supplementation, low (40g), medium, (80g) and high (160g), will remain constant throughout each 4-day period, and the order will be individually randomised.
Study: NCT06362785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The intervention group will engage in immersive virtual reality sessions with interactive activities involving functional movements of the spine and limbs in a virtual environment using Meta Quest 3 goggles. The intervention will last for 6 weeks, comprising a total of 12 sessions, with a maximum duration of 30 minutes of virtual reality and 15 minutes of rest (45 minutes in total per session).
Study: NCT04955925

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination of the optic nerve sheath diameter
Description: The optic nerve sheath diameter is examined using ultrasonography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound examination of the optic nerve sheath diameter
Description: The optic nerve sheath diameter is examined using ultrasonography.
Study: NCT06739551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (drug)
Description: oral methotrexate 10 mg per week for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: oral acitretin 50 mg once daily for 12 weeks
Study: NCT06740591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: The HD-tDCS stimulation was applied for 20 minutes, 5 times a week, for a total of 10 sessions.
Study: NCT05319704

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Test of effort on cycle on concentric or excentric mode
Description: participants may receive 4 interventions sequentially during the protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test of effort on cycle on concentric or excentric mode
Description: participants may receive 4 interventions sequentially during the protocol
Study: NCT06740591

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High-Definition Transcranial Direct Current Stimulation(sham HD-tDCS)
Description: The Sham HD-tDCS stimulation was applied for 20 minutes, 5 times a week, for a total of 10 sessions.
Study: NCT06739720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LingZhi capsule
Description: Lingzhi-containg capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm CO LTD containing: wild red ganoderma extract, ganoderma spore powder (99.9% broken wall), β-nicotinamide mononucleotide (NMN), wild yellow ganoderma extract, wild green ganoderma extract, wild purple ganoderma extract, wild white ganoderma extract, wild black sesame extract
Study: NCT06738095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: daily low-level red-light
Description: Daily low-level red-light is a kind of myopia intervention. Red-light typically using 650-nm wave of length. The treatment duration last 3 minutes each time, every day children were anticipated to use two times, at home.
Study: NCT06740370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
Study: NCT06568094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5041 tablets
Description: HRS-5041 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5041 tablets
Description: HRS-5041 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5041 tablets
Description: HRS-5041 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5041 tablets
Description: HRS-5041 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate tablets（II）
Description: Abiraterone Acetate tablets（II）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Acetate tablets
Description: Prednisone Acetate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Acetate tablets
Description: Prednisone Acetate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Injection
Description: Docetaxel Injection
Study: NCT05319704

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Test of effort on cycle on concentric or excentric mode
Description: participants may receive 4 interventions sequentially during the protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test of effort on cycle on concentric or excentric mode
Description: participants may receive 4 interventions sequentially during the protocol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinetics on concentric or excentric mode during test of effort
Description: participants may receive 4 interventions sequentially during the protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinetics on concentric or excentric mode during test of effort
Description: participants may receive 4 interventions sequentially during the protocol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinetics on concentric or excentric mode during test of effort
Description: participants may receive 4 interventions sequentially during the protocol
Study: NCT06568094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167 tablets
Description: HRS-1167 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554 tablets
Description: SHR2554 tablets
Study: NCT04925570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: W-SUDs
Description: Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.

Intervention type: OTHER
Group type: OTHER
Intervention: Digitally-delivered Psychoeducation
Description: A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
Study: NCT05142241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT06585306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: jaw lift, increasing oxygen flow, mask ventilation, intubation
Description: When patients develop hypoxemia, the above interventions are sequentially employed to improve their oxygenation status.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: jaw lift, increasing oxygen flow, mask ventilation, intubation
Description: When patients develop hypoxemia, the above interventions are sequentially employed to improve their oxygenation status.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: jaw lift, increasing oxygen flow, mask ventilation, intubation
Description: When patients develop hypoxemia, the above interventions are sequentially employed to improve their oxygenation status.
Study: NCT05116969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody
Study: NCT04954677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-box
Description: Automatic quality-control system（AI-box）could real-time measure endoscopic inspection completeness, evaluate gastric cleanliness.
Study: NCT05021926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKL crosslinked sodium hyaluronate 26
Description: is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 26 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm Voluma™ with lidocaine (Allergan, Inc)
Description: is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Voluma™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
Study: NCT04835363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Occupational Therapy intervention
Description: four-week OT intervention program with the support of the main caregiver in patients who have suffered a stroke with the aim of improving the functional result and facilitating the return home by providing knowledge to the caregiver about specific care and neurorehabilitation.
Study: NCT05319704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinetics on concentric or excentric mode during test of effort
Description: participants may receive 4 interventions sequentially during the protocol
Study: NCT06467019

Intervention type: OTHER
Intervention: Informative Session
Description: The intervention consists of implementing an interactive exhibition on the risks of chronic benzodiazepine treatment in the waiting room of a primary care center. Additionally, the health professionals at the center will receive a single informative session on the same topic.
Study: NCT05542602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social intervention
Description: The social intervention consists of four 90-minute sessions per week delivered over eight weeks by paraprofessional staff as part of the children's existing after-school program. The sessions follow a schedule and include social skills groups, social recreational games, and a reinforcement system to teach, practice, and reinforce targeted social knowledge and social skills. The sessions are manualized and include a specific instructional sequence and treatment (lesson) plan for the paraprofessional staff to implement. The children also earn points for use of the targeted skills (frequency of use) and each can earn a home or site-based reinforcer for reaching her/his targeted number of points each session. Each group is facilitated by two paraprofessionals, and includes 12-15 children including two with hfASD (the remaining will be typically-developing peers).
Study: NCT06071988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adezunap (AP707)
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT06237491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1003 Injection group 1
Description: The treatment regimen will consist of a single dose 30 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1003 Injection group 2
Description: The treatment regimen will consist of a single dose 50 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-LNC1003 Injection group 3
Description: The treatment regimen will consist of a single dose 70 mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
Study: NCT06057857

Intervention type: OTHER
Intervention: conventional oral examination
Description: conventional oral examination
Study: NCT05086835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Working Memory Task
Description: A smartphone-based visual-spatial working memory task that will be optimized in the Stage 1A phase of this study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Search Task
Description: A smartphone-based visual search task that will be optimized in the Stage 1A phase of this study.
Study: NCT06099795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eBAM Cov Testing
Description: Evaluation of presence/absence of infection with SARS-CoV-2 assessed by eBAM-CoV on air exhaled by the patient compared with the presence/absence of infection based on RT-PCR testing of nasopharyngeal swabs
Study: NCT05369884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPQW granule
Description: WPQW granule, 2 sachets / time, 3 times / day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WPQW granule simulant
Description: WPQW granule simulant, 2 sachets / time, 3 times / day.